UBE2N

Across TCGA pan-cancer cohorts, UBE2N mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of UBE2N’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where UBE2N mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types UBE2N is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.

PDAC, CCRCC, and COAD are the cancer types where UBE2N tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2N mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−0.470	<.001	9	view →
CCRCC	Female	III,IV	+0.131	.024	4	view →
COAD	All	II,III,IV	−0.085	.004	4	view →
HNSC	All	IV	+0.122	.002	2	view →
LSCC	All	All	+0.051	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

UBE2N–PDAC

Open the PDAC breakdown →